Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking and Finance Review

Global Banking & Finance Review

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2025 GBAF Publications Ltd - All Rights Reserved.

    ;
    Editorial & Advertiser disclosure

    Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Exclusive-AstraZeneca pauses $270 million investment in Britain
    Finance

    Exclusive-AstraZeneca pauses $270 million investment in Britain

    Exclusive-AstraZeneca pauses $270 million investment in Britain

    Published by Global Banking and Finance Review

    Posted on September 12, 2025

    Featured image for article about Finance

    By Alistair Smout and Maggie Fick

    LONDON (Reuters) - Britain's biggest company AstraZeneca has paused a planned 200 million pound ($271.26 million) investment in its Cambridge research site, a spokesperson said, the latest drugmaker to retreat from Britain.

    The decision on the investment, which had been set to create 1,000 jobs, means none of AstraZeneca's planned new funding - originally announced in March 2024 - is currently proceeding.

    In January, the company scrapped plans to invest 450 million pounds in its vaccine manufacturing plant in northern England, citing a cut in British government support.

    U.S. drugmaker Merck & Co this week blamed the UK's challenging business environment as it abandoned a new research centre in London.

    Asked about speculation over its pharmaceutical investments following the Merck announcement, a spokesperson for AstraZeneca, which has the biggest market capitalisation on the FTSE 100, confirmed it would pause its investment plans in Cambridge, where it has one of Britain's leading life sciences hubs.

    "We constantly reassess the investment needs of our company and can confirm our expansion in Cambridge is paused. We have no further comment to make," an AstraZeneca spokesperson said.

    The news, which will come as a blow to Prime Minister Keir Starmer's government and its efforts to draw investment into the UK's stagnant economy, comes just days before U.S. President Donald Trump arrives in Britain for a state visit.

    AstraZeneca in July said it would spend $50 billion to expand manufacturing and research capabilities in the United States by 2030 - one of many announcements by pharmaceutical companies reacting to Trump's tariff policy.

    Trump has criticised Britain and Europe for not paying high enough prices for drugs, and several pharmaceutical firms have criticised Britain for what they say is long-term undervaluation of medicines and innovation.

    After AstraZeneca dropped its vaccine plant investment plan, Chief Executive Pascal Soriot urged Britain to improve the environment for businesses in order to drive investment.

    ($1 = 0.7373 pounds)

    (Reporting by Alistair Smout and Maggie Fick; Editing by Kirsten Donovan)

    Related Posts
    Shell mergers chief Greg Gut quits after CEO blocks bid for BP, FT reports
    Shell mergers chief Greg Gut quits after CEO blocks bid for BP, FT reports
    Exclusive-Britain examines revamp of capital rules for likes of Citadel and XTX
    Exclusive-Britain examines revamp of capital rules for likes of Citadel and XTX
    Oil slips on Russia-Ukraine peace deal talks, weak China data
    Oil slips on Russia-Ukraine peace deal talks, weak China data
    Stocks slide as investors on edge ahead of data, central bank meetings
    Stocks slide as investors on edge ahead of data, central bank meetings
    Human‑wave attacks and drones: How Myanmar's junta is fighting back
    Human‑wave attacks and drones: How Myanmar's junta is fighting back
    When Banking Delays Cross the Line: Legal Rights Around Held Checks
    When Banking Delays Cross the Line: Legal Rights Around Held Checks
    EU to relent on combustion engines ban after auto industry pressure
    EU to relent on combustion engines ban after auto industry pressure
    Dollar on defensive as traders eye delayed US jobs data
    Dollar on defensive as traders eye delayed US jobs data
    US suspends technology deal with Britain, FT reports
    US suspends technology deal with Britain, FT reports
    QuantumDiamonds announces 152 million euros investment plan for new Munich site
    QuantumDiamonds announces 152 million euros investment plan for new Munich site
    British regulator kicks off consultation on new crypto rules
    British regulator kicks off consultation on new crypto rules
    Trump sues the BBC for defamation over editing of January 6 speech, seeks up to $10 billion in damages
    Trump sues the BBC for defamation over editing of January 6 speech, seeks up to $10 billion in damages

    Why waste money on news and opinions when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Previous Finance PostMorgan Stanley, Deutsche Bank expect three US interest rate cuts this year
    Next Finance PostTesla chair says Musk's political activity 'up to him,' dismisses sales concerns

    More from Finance

    Explore more articles in the Finance category

    Europe to launch international commission for Ukraine war damages

    Europe to launch international commission for Ukraine war damages

    South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi

    South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi

    Uniper to launch sale of 20% stake in Opal gas pipeline

    Uniper to launch sale of 20% stake in Opal gas pipeline

    Trading Day: Payrolls, Fed jitters mount

    Trading Day: Payrolls, Fed jitters mount

    'Battlefield' maker EA forecasts softer 2026 bookings amid slow spending, crowded holiday slate

    'Battlefield' maker EA forecasts softer 2026 bookings amid slow spending, crowded holiday slate

    Britain clinches upgraded South Korea trade deal

    Britain clinches upgraded South Korea trade deal

    Trump says lawsuit against BBC likely to be filed soon

    Trump says lawsuit against BBC likely to be filed soon

    Tesla shares jump as Musk confirms driverless robotaxi testing

    Tesla shares jump as Musk confirms driverless robotaxi testing

    Italy's competition authority drops probe into Eni's Plenitude unit

    Italy's competition authority drops probe into Eni's Plenitude unit

    Bridgewater warns Big Tech's reliance on external capital to fund AI boom is 'dangerous'

    Bridgewater warns Big Tech's reliance on external capital to fund AI boom is 'dangerous'

    Italian firms using AI double in a year but still small minority

    Italian firms using AI double in a year but still small minority

    Juventus shares soar 19% after Agnelli family rejects crypto firm Tether's bid

    Juventus shares soar 19% after Agnelli family rejects crypto firm Tether's bid

    View All Finance Posts